瑞舒伐他汀对老年冠心病患者造影剂肾病的预防作用和对血脂的影响
《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]
- 期数:
- 2016年第4期
- 页码:
- 464-467
- 栏目:
- 临床研究
- 出版日期:
- 2016-04-01
文章信息/Info
- Title:
- Preventive effect of rosuvastatin on contrast-induced nephropathy and blood lipids in elderly patients with coronary heart disease
- Author(s):
- JIANG Man1; ZHANG Hua1; GU Xin1; ZHOU Min1; FU Xue-feng2
- (1.Department of Pharmacy, PLA General Hospital of Air Force, Beijing 100142, China；
2.Department of Veteran Cadres, Lanzhou General Hospital, Lanzhou Military Area Command, Lanzhou 730050, Gansu, China)
- 分类号:
- R595.3;R541.4
- DOI:
- -
- 文献标识码:
- A
- 摘要:
- 目的 观察瑞舒伐他汀对老年冠心病患者造影剂肾病（CIN）的预防作用和对血脂的影响。方法 2014年1月~2014年12月确诊的老年冠心病患者114(男67，女47)例，年龄61~83岁，随机分为常规治疗组（n=57）和瑞舒伐他汀组（n=57）。瑞舒伐他汀组在常规治疗的基础上加服瑞舒伐他汀，每晚20 mg，连续8周。两组分别于造影前、造影后24 h、72 h和7 d测定尿素氮（BUN）及血肌酐（SCr）水平并计算内生肌酐清除率（CCr），同时测定血脂水平。结果 造影前常规治疗组与瑞舒伐他汀组肾功能无显著差异，但瑞舒伐他汀组血脂明显低于常规治疗组（P<0.05，P<0.01）。常规治疗组造影后24 h、72 h BUN和SCr明显高于造影前（P<0.05，P<0.01），而CCr则明显降低（P<0.01），血脂无明显变化，这些变化均于7 d后恢复正常。瑞舒伐他汀组造影后仅SCr在24 h、72 h较造影前升高（P<0.05），BUN和CCr无明显变化。常规治疗组发生CIN 6例（11%）于7 d后恢复，瑞舒伐他汀组无发生CIN病例，与常规治疗组CIN发生率比较有显著差异（P<0.05)。两组造影前后血脂均无显著变化。两组不良反应发生率无统计学差异。结论 瑞舒伐他汀对老年冠心病患者具有降血脂作用和对CIN有显著预防作用。
- Abstract:
- AIM To investigate the preventive effect of rosuvastatin on preventive contrast-induced nephropathy (CIN) and blood lipid levels in elderly patients with coronary heart disease. METHODSFrom January-December 2014, 114 patients (67 male, 47 female) with coronary heart disease, aged 61-83 years, were randomly divided into conventional treatment group (n=57) and rosuvastatin group (n=57). The rosuvastatin group was given rosuvastatin orally, 20 mg/night for 8 weeks. Blood urea nitrate (BUN) and serum creatinine (SCr) levels were measured in both groups, respectively, before surgery and 24 h, 72 days and 7 days after surgery. Endogenous creatinine clearance rate (CCr) was calculated and blood lipid levels were tested at the same time. RESULTSNo difference in renal function was observed between conventional group and rosuvastatin group before surgery; however, serum lipids were significantly lower in the rosuvastatin group (P<0.05, P<0.01). In the conventional treatment group, BUN and SCr 24 h and 72 h after surgery were significantly higher than those before surgery (P<0.05, P<0.01), CCr decreased significantly (P<0.01) and no significant change was found in blood lipids. These changes returned to normal after 7 days. In the rosuvastatin group, SCr increased (P<0.05) and no significant change was found in BUN and CCr 24 h and 72 h after surgery. There were six cases (11%) of CIN in the conventional group and they recovered after 7 days, and no CIN case in the rosuvastatin group. There were no significant changes in blood lipids in both groups before and after surgery. Difference in the incidence of adverse reactions between groups was not statistically significant. CONCLUSIONRosuvastatin reduces the effect of serum lipids and has a beneficial preventive effect of CIN in elderly patients with coronary heart disease.
参考文献/References
[1]Brueck M,Cengiz H,Hoeltgen R,et al.Usefulness of N-acetylcysteine or ascorbic acid versus placebo to prevent contrast-induced acute kidney injury in patients undergoing elective cardiac catheterization: a single-center, prospective,randomized,double-blind,placebo-controlled trial[J].J Invasive Cardiol,2013,25(6):276-283.
[2]Cheungpasitporn W,Thongprayoon C,Kittanamongkolchai W,et al.Periprocedural effects of statins on the incidence of contrast-induced acute kidney injury:a systematic review and meta-analysis of randomized controlled trials[J].Ren Fail,2015,37(4):664-671.
[3]彭 伟,李长运,王一丹.术前强化阿托伐他汀治疗对冠状动脉介入术后造影剂肾病的影响[J].中华临床医师杂志(电子版),2012,6(16):4952-4954.
[4]Yeboah J,Sillau S,Delaney JC,et al.Implications of the new American College of Cardiology/American Heart Association cholesterol guidelines for primary atherosclerotic cardiovascular disease event prevention in a multi ethnic cohort: Multi-Ethnic Study of Atherosclerosis(MESA)[J].Am Heart J,2015,169(3):387-395.e3.
[5]丁文飞,王金艳,钟爱民.造影剂肾病的发病机制研究进展[J].江西医药,2014,49(6):554-556.
[6]叶应妩,王毓三,申子瑜.全国临床检验操作规程[M].第3版,南京:东南大学出版社,2006:474-483.
[7]Horváth Z,Csuka D,Vargova K,et al.Elevated C1rC1sC1inh levels independently predict atherosclerotic coronary heart disease[J].Mol Immunol,2013,54(1):8-13.
[8]中国成人血脂异常防治指南制定联合委员会.《中国成人血脂异常防治指南》标准[J].中华心血管病杂志,2007,35(5):1-30.
[9]Narula J,Nakano M,Virmani R,et al.Histopathologic characteristics of atherosclerotic coronary disease and implications of the findings for the invasive and noninvasive detection of vulnerable plaques[J].J Am Coll Cardiol,2013,61(10):1041-1051.
[10]Kataoka Y,Hammadah M,Puri R,et al.Plaque microstructures in patients with coronary artery disease who achieved very low low-density lipoprotein cholesterol levels[J].Atherosclerosis,2015,242(2):490-495.
[11]Wong MC,Zhang DX,Wang HH.Rapid emergence of atherosclerosis in Asia:a systematic review of coronary atherosclerotic heart disease epidemiology and implications for prevention and control strategies[J].Curr Opin Lipidol,2015,26(4):257-269.
[12]Gao WQ,Feng QZ,Li YF,et al.Systematic study of the effects of lowering low-density lipoprotein- cholesterol on regression of coronary atherosclerotic plaques using intravascular ultrasound[J].BMC Cardiovasc Disord,2014,14:60.
[13]Dai W,Li Y,Lv YN,et al.The roles of a novel anti-inflammatory factor, milk fat globule-epidermal growth factor 8, in patients with coronary atherosclerotic heart disease[J].Atherosclerosis,2014,233(2):661-665.
[14]Li J,Zhang L,Xie NZ,et al.Relationship between the cholesterol ester transfer protein TaqIB polymorphism and the lipid-lowering effect of atorvastatin in patients with coronary atherosclerotic heart disease[J].Genet Mol Res,2014,13(1):2140-2148.
备注/Memo
- 备注/Memo:
- 收稿日期：2015-11-04.
基金项目：军队医药卫生科研基金资助（CLZ11JB02）；兰州军区医药卫生科研资金资助（CLZ11JB02）
通讯作者：付学锋，主任医师，硕士，主要从事老年性疾病的诊断和治疗的研究 Email:xuct2001@163.com
作者简介：江漫，主管药师，硕士 Email:xuct2001@qq.com
常用功能
统计/Statistics
- 摘要浏览/Viewed753
- 评论/Comments
